Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.90+0.06 (+1.56%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Nuvation Bio total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Nuvation Bio's total debt was $5.89M at Jun 30, 2026. For fiscal 2025 it was $5.72M, down 8.9% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.72M | -8.9% |
| FY2024 | Dec 31, 2024 | $6.28M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.89M | +5.6% |
| Q1 FY2026 | Mar 31, 2026 | $5.79M | +1.8% |
| Q4 FY2025 | Dec 31, 2025 | $5.72M | -8.9% |
| Q3 FY2025 | Sep 30, 2025 | $5.62M | -33.3% |
| Q2 FY2025 | Jun 30, 2025 | $5.58M | -52.0% |
| Q1 FY2025 | Mar 31, 2025 | $5.69M | – |
| Q4 FY2024 | Dec 31, 2024 | $6.28M | – |
| Q3 FY2024 | Sep 30, 2024 | $8.43M | – |
| Q2 FY2024 | Jun 30, 2024 | $11.63M | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
See a number that looks wrong?